rs55778349
From SNPedia
| Orientation | plus |
| Stabilized | plus |
| Geno | Mag | Summary |
|---|---|---|
| (G;G) | 0 | common in clinvar |
| Make rs55778349(C;C) |
| Make rs55778349(C;G) |
| Reference | GRCh38 38.1/141 |
| Chromosome | 19 |
| Position | 17843141 |
| Gene | JAK3 |
| is a | snp |
| is | mentioned by |
| dbSNP | rs55778349 |
| dbSNP (classic) | rs55778349 |
| ClinGen | rs55778349 |
| ebi | rs55778349 |
| HLI | rs55778349 |
| Exac | rs55778349 |
| Gnomad | rs55778349 |
| Varsome | rs55778349 |
| LitVar | rs55778349 |
| Map | rs55778349 |
| PheGenI | rs55778349 |
| Biobank | rs55778349 |
| 1000 genomes | rs55778349 |
| hgdp | rs55778349 |
| ensembl | rs55778349 |
| geneview | rs55778349 |
| scholar | rs55778349 |
| rs55778349 | |
| pharmgkb | rs55778349 |
| gwascentral | rs55778349 |
| openSNP | rs55778349 |
| 23andMe | rs55778349 |
| SNPshot | rs55778349 |
| SNPdbe | rs55778349 |
| MSV3d | rs55778349 |
| GWAS Ctlg | rs55778349 |
| GMAF | 0.003214 |
| Max Magnitude | 0 |
| ClinVar | |
|---|---|
| Risk | rs55778349(C;C) |
| Alt | rs55778349(C;C) |
| Reference | Rs55778349(G;G) |
| Significance | Other |
| Disease | Severe combined immunodeficiency disease not specified not provided |
| Variation | info |
| Gene | JAK3 |
| CLNDBN | Severe combined immunodeficiency disease not specified not provided |
| Reversed | 0 |
| HGVS | NC_000019.9:g.17953950G>C |
| CLNSRC | UniProtKB (protein) |
| CLNACC | RCV000030094.1, RCV000121271.2, RCV000224911.1, |
[PMID 17433] [Inhibition of 4-aminobutyrate transaminase by ethanolamine-O-sulfate].
[PMID 10900158] Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency.
[PMID 10982185] Complete genomic organization of the human JAK3 gene and mutation analysis in severe combined immunodeficiency by single-strand conformation polymorphism.
[PMID 11668610] Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency.
[PMID 17456055] Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.
[PMID 20132407
] Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases.
